Department of pharmaceuticals , ministry of chemical and fertilizers release guidelines for the scheme strengthening of pharmaceuticals industry.

Department of pharmaceuticals , ministry of chemical and fertilizers release guidelines for the scheme strengthening of pharmaceuticals industry.

Guidelines for the Scheme for “Strengthening of Pharmaceuticals Industry (SPI)

Objective of the Scheme

• To strengthen the existing infrastructure facilities in order to make India a global leader in Pharma Sector by providing financial assistance to pharma clusters for creation of Common Facilities to improve the quality and ensure the sustainable growth of cluster.
• To upgrade the production facilities of SMEs and MSMEs, to meet national and international regulatory standards, by providing interest subvention or capital subsidy on their capital loans, which will facilitate the growth in volumes as well as in quality; and Guidelines for the Scheme – Strengthening of Pharmaceuticals Industry (SPI) .
• To promote knowledge and awareness in and about the Pharmaceutical and Medical Devices Industry by taking up studies, building databases and bringing industry leaders, academia and policy makers together to share their knowledge and experience for overall development of Pharma and Medical Devices industry.

Components of the Scheme

The Scheme shall have 3 components / sub-schemes:

1. Assistance to Pharmaceutical Industry for Common Facilities (APICF) To strengthen the existing pharmaceutical clusters’ capacity for their sustained growth by creating common facilities.
2. Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) To facilitate Micro, Small and Medium Pharma Enterprises (MSMEs) of proven track record to meet national and international regulatory standards.

• Pharmaceutical & Medical Devices Promotion and Development Scheme (PMPDS) To facilitate growth and development of Pharmaceutical and Medical Devices Sectors through study/survey reports, awareness programs, creation of database, and promotion of industry.

Details of the Sub-Schemes:

Assistance to Pharmaceutical Industry for Cluster Facility (APICF)

• Objective To strengthen the existing pharmaceutical clusters’ capacity for their sustained growth by creating tangible assets as “Common Facilities”.
• Incentive under the scheme

The limit of incentive will be 70% of the approved project cost or Rs 20 cr., whichever is less, as per approval of SSC. In the case of Himalayan States and States in the North East Region, the grant-in-aid would be Rs. 20 Crore per Cluster or 90% of the project cost of the Common Infrastructure Facilities (CIF), whichever is less.

Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS)

• Objectives To facilitate Micro, Small and Medium Pharma Enterprises (MSME) of proven track record to upgrade their technology to meet WHO-GMP or Schedule M standards.
• Intended Beneficiaries Micro, Small and Medium Enterprises of pharma sector.

 Incentive under the scheme

• Up to maximum of 5% per annum (6% in case of units owned and managed by SC/STs) of interest subvention for loan component eligible under the scheme taken to the upper limit of Rs. 10 cr.
• For a maximum period of 3 years on reducing balance for sanctioned loans by any scheduled commercial banks/financial institutions, both in the Public and the Private Sector.

Pharmaceutical & Medical Devices Promotion and Development Scheme (PMPDS)

• Objective The scheme has two main objectives. The first objective is to promote Pharmaceutical and Medical Device Industry by bringing industry leaders, academia and policy makers together to share their knowledge and experience for overall development of the sectors. The other objective of the scheme is to facilitate growth and development of the sectors through conducting studies, organizing awareness programs, creation of databases and promotion of industry.
• Intended Beneficiaries The pharmaceutical and medical devices industry in India will be the beneficiary of this scheme. Grants will be provided to any of the followings:- a. Recognized Industry associations that are significantly representative. b. Organizations/Firms with track record in conducting studies/survey etc. in Pharmaceuticals, medical devices and related sectors. c. Government/quasi-government agencies with relevant experience.